India Glycols Plans Demerger Amid Strong FY26 Performance

FY26 PAT ₹293 Cr (+26.8% YoY), FY26 Revenue ₹4,211 Cr (+11.8% YoY).
Reader Takeaway: PAT surge on broad growth; demerger offers value unlock, but Ennature margins feel pressure.

What just happened (today’s filing)

India Glycols Limited (IGL) has posted strong financial results for the fiscal year ending March 2026 (FY26). Consolidated net revenue grew by 11.8% year-on-year to ₹4,211 crore, while Profit After Tax (PAT) saw a significant jump of 26.8% to ₹293 crore. The fourth quarter of FY26 also demonstrated robust performance, with PAT rising 35.7% to ₹87 crore on a 13.1% revenue increase to ₹976 crore.

In parallel, the company is undertaking a major corporate restructuring. The scheme to demerge its Potable Spirits, Bio-fuel, and Bio-pharma businesses into separate entities has been admitted by the National Company Law Tribunal (NCLT). A further hearing is scheduled for May 21, 2026.

Why this matters

The proposed demerger aims to unlock value by creating distinct, focused companies for each business segment. This could lead to specialized management, tailored strategies, and potentially higher valuations for the demerged entities as investors can assess each business independently.

The backstory (grounded)

IGL has strategically expanded its ethanol production capacity, aligning with the government's push for biofuels and increasing reliance on molasses-based green chemistry. The company has a history of diversifying its revenue streams, focusing on downstream products and high-value specialty chemicals.

What changes now

• The Potable Spirits, Bio-fuel, and Bio-pharma businesses will operate as independent companies.
• This separation allows for focused management and capital allocation for each distinct operation.
• Post-restructuring, the promoter group is expected to hold approximately 59.63% in each of the three resulting entities.
• It sets the stage for potential value unlocking and improved market perception for specialized segments.

Risks to watch

• EBITDA margins within the Ennature Biopharma segment are under pressure due to lower sales of Nicotine and elevated raw material costs for Gloriosa seeds.
• General softening of demand is noted in some end-user markets, influenced by global geopolitical situations.

Peer comparison

IGL's diversified nature places it against varied peers. Competitors like GHCL Ltd are benchmarks for chemical operations, while Som Distilleries & Breweries Ltd offers a comparison for the potable spirits segment. Balaji Amines Ltd provides a view into specialty chemical players, although with different product focuses.

Context metrics (time-bound)

• Consolidated EBITDA for FY26 stood at ₹654 Cr, marking a 24.5% YoY increase.
• Consolidated EBITDA for Q4 FY26 was ₹167 Cr, up 13.3% YoY.
• The Potable Spirits segment reported revenue of ₹1,331 Cr for FY26.

What to track next

• The crucial NCLT hearing outcome on May 21, 2026, for the demerger scheme.
• Future financial performance reports from the demerged entities post-restructuring.
• Management commentary on the strategic direction and growth plans for each new company.